N- terminal pro brain natriuratic peptide (nt-probnp) in apparently healthy subjects compared to metabolic syndrome subjects

Zaidan Azeez  Hasan; Dhia Mustafa  Sulaiman

doi:10.56056/amj.2022.142

Authors

Zaidan Azeez Hasan MBChB; Medical Board Student in Medical Biochemistry Azadi Teaching Hospital, Duhok General Directorate of Health
Dhia Mustafa Sulaiman PhD in Clinical Biochemistry. Department of Medical Laboratory Technology, Shekhan Technical College of Health, Duhok Polytechnic University, Duhok, Iraq

DOI:

https://doi.org/10.56056/amj.2022.142

Keywords:

Metabolic syndrome, Nt-proBNP, Risk factors

Abstract

Background and objectives: B –type natriuretic peptide is synthesized in myocardial cells to respond to increased wall stress in association with heart failure or acute myocardial ischemia. High B –type natriuretic peptide and high Nt-pro B –type natriuretic peptide levels are candidates for cardiovascular risk markers and hypertension, left ventricular hypertrophy, and albuminuria. The level and relation of Nt-pro B –type natriuretic peptide with metabolic syndrome was examined in this study.

Methods: In this case-control investigation, the level of Nt-pro B –type natriuretic peptide of 80 metabolic syndrome patients diagnosed based on the International Diabetes Federation guidelines was compared to its level in 40 healthy controls. The subjects who accompanied the diabetic patients at Duhok Diabetes Center were screened for inclusion and exclusion criteria between the first March and May 2019.

Results: The concentrations of triglyceride (215.09 vs. 104.02 mg/dL), total cholesterol (179.68 vs. 162.75mg/dL), and fasting blood glucose (188.71 vs. 88.08 mg/dL) were significantly higher in metabolic syndrome patients compared to the healthy controls, respectively. Nt-pro B –type natriuretic peptide was significantly lower in patients in contrast with healthy individuals (35.00 vs. 46.00 pg/mL), respectively. However, the proBNP level was not significantly different in metabolic syndrome patients with normal and abnormal biochemical parameters.

Conclusions: This study showed a significantly lower concentration of Nt-proBNP in metabolic syndrome compared to healthy controls. However, the study did not find a significant correlation with the content of metabolic syndrome.

Downloads

Download data is not yet available.

References

-Raizada V, Thakore K, Luo W, McGuire P. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem. 2001;216(1-2):137-40.

-Yandle TG, Richards AM. B-type natriuretic peptide circulating forms: analytical and bioactivity issues. Clinica Chimica Acta. 2015; 448:195-205.

-Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-68.

-Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-7.

-Oremus M, McKelvie R, Don-Wauchope A, et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. Heart Fail Rev. 2014;19(4):413-9.

-Piechota M, Banach M, Jaco? A, Rysz J. Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett. 2008;13(2):155.

-Sattar N, John Danesh F. B-Type Natriuretic Peptides and Cardiovascular Risk. Circulation. 2009; 120:2177-87.

-Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109(5):594-600.

-Wang TJ, Larson MG, Keyes MJ, et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115(11):1345-53.

-Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The lancet. 2005;365(9468):1415-28.

-Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735-52.

-Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005;46(4):660-6.

-Dessì-Fulgheri P, Sarzani R, Tamburrini P, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens1997;15(12):1695-8.

-Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. The lancet. 2010;375(9710):181-3.

-Bao Y, Shang X, Zhou L, et al. Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci. 2011;7(2):247-56.

-Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: Diabet Med. 2006;23(5):469-80.

-Allanore Y, Borderie D, Meune C, et al. N?terminal pro–brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium?channel blockers. Arthritis Rheum. 2003;48(12):3503-8.

-Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43(9):1590-5.

-Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580-5.

-Licata G, Volpe M, Scaglione R, Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension. 1994;23(1_supplement): I20-I4.

-De GP, Garruti G, Giorgino F, et al. Reduced effectiveness of atrial natriuretic factor in pre-menopausal obese women. Int J Obes Relat Metab Disord. 1994;18(2):93-7.

-Nannipieri M, Seghieri G, Catalano C, et al. Defective regulation and action of atrial natriuretic peptide in type 2 diabetes. Horm Metab Res 2002;34(05):265-70.

-Moro C, Polak J, Richterova B, et al. Differential regulation of atrial natriuretic peptide–and adrenergic receptor–dependent lipolytic pathways in human adipose tissue. Metabolism. 2005; 54(1):122-31.

-Sarzani R, Strazzullo P, Salvi F, et al. Natriuretic peptide clearance receptor alleles and susceptibility to abdominal adiposity. Obes Res. 2004;12(2):351-6.

-Raymond I, Groenning B, Hildebrandt Py, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart. 2003;89(7):745-51.

-Chang H-R, Hsieh J-C, Chen MY-C, et al. N-terminal pro-B-type natriuretic peptide is inversely associated with metabolic syndrome in hypertensive patients. Am J Med Sci. 2014;348(3):210-4.

-Hassan II, Hassan AB, Rajab HA, et al. Association of irisin and oxidative stress with biochemical parameters in patients with metabolic syndrome. Horm Mol Biol Clin Investig. 2019;39(1).

-Bertoni AG, Wagenknecht LE, Kitzman DW, et al. Impact of the Look AHEAD Intervention on NT?pro Brain Natriuretic Peptide in Overweight and Obese Adults with Diabetes. Obesity. 2012;20(7):1511-8.

-Lazo M, Young JH, Brancati FL, et al. NH2-terminal pro–brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62(9):3189-93.